The federal effort to move cannabis from Schedule I to Schedule III of the Controlled Substances Act now faces a coordinated legal challenge from inside the Republican Party itself. Attorneys general from Indiana, Nebraska, and Louisiana filed suit in the U.S. Court of Appeals for the D.C. Circuit this month, arguing the rescheduling action announced by Acting Attorney General Todd Blanche is procedurally defective, exceeds statutory authority, and should be vacated. For the licensed cannabis industry - operators, investors, compliance teams - this is the kind of legal turbulence that can stall regulatory progress for years.
What the AGs Are Actually Arguing
The filing is not a policy disagreement dressed up in legal language. It makes specific procedural claims: that the rescheduling order fails to satisfy the rulemaking requirements of the Administrative Procedure Act (APA) and section 201 of the Controlled Substances Act, that it was "improperly promulgated," and that it constitutes an arbitrary and capricious exercise of agency discretion. That last phrase carries particular weight under APA doctrine - it's a standard courts use to strike down agency actions that lack a reasoned, documented basis.
The AGs' petition has now been consolidated with an earlier suit filed by Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association (NDASA). SAM retained the law firm of former Attorney General William Barr - who led DOJ during Trump's first term - to bring the challenge. That's not an incidental detail. Barr's firm carries institutional credibility in federal administrative law, and having counsel with that profile attached to the consolidated case raises the probability that these arguments receive serious judicial attention.
The Mechanics of the Rescheduling Order Under Challenge
Blanche's action, announced last month, moved marijuana products regulated under a state medical cannabis license immediately to Schedule III, along with any FDA-approved marijuana products. A broader administrative hearing is still scheduled for next month to address rescheduling for recreational products. Here's the catch: the mechanism Blanche used - an order from the Attorney General rather than a full notice-and-comment rulemaking - is precisely what the challengers are attacking.
Under the CSA, the rescheduling process ordinarily involves DEA initiating a formal rulemaking, collecting public comment, and working through a process with scientific review components. The SAM and NDASA petition alleges the AG Rescheduling Order bypassed those requirements. Whether or not a court ultimately agrees, the structural question is legitimate: agency shortcuts, even well-intentioned ones, tend to generate durable legal exposure. The Biden administration's rescheduling proposal went through notice-and-comment. The Trump DOJ's order, by contrast, moved faster and differently - and that procedural divergence is now the center of the litigation.
What This Means for Licensed Operators Right Now
To put it plainly: no dispensary operator should be adjusting compliance infrastructure, tax strategy, or banking relationships based on Schedule III status until the litigation resolves - and that resolution is not imminent.
The operational stakes are real. Schedule III reclassification, if it survives legal challenge, would remove cannabis from the IRS's 280E tax provision, which currently denies standard business deductions to plant-touching cannabis companies. That's the single most consequential financial change rescheduling would trigger for licensed retailers. A dispensary paying effective tax rates well above those of comparable non-cannabis retail businesses would, under Schedule III, regain the ability to deduct ordinary cost-of-goods and operating expenses. The difference in net income, at scale, is material.
But that outcome now sits behind a wall of litigation - and behind a House committee vote earlier this month that moved to block federal officials from taking further steps to carry out rescheduling. The legislative and judicial challenges are running simultaneously. Multi-state operators with sophisticated legal and tax counsel are almost certainly treating 280E relief as contingent, not certain, for current fiscal planning.
Banking and payments remain constrained in the interim. Financial institutions evaluating whether to extend services to cannabis businesses have consistently pointed to federal scheduling as a primary compliance barrier. Schedule III would reduce - though not eliminate - that risk calculus. With the rescheduling order now under active litigation, expect cautious institutions to remain exactly where they've been. The uncertainty itself is the problem.
A Consolidating Opposition - and What Comes Next
What's striking about the consolidated litigation is the alignment it represents. Three Republican state AGs, a prominent prohibitionist advocacy organization, and a drug-testing industry group are now in the same proceeding - with Barr's firm providing legal muscle. SAM has separately seen a related Medicare hemp-benefit challenge dismissed, but this rescheduling case is a different matter: it targets a formal agency action through a court with jurisdiction to vacate it.
Named defendants include the Department of Justice, the DEA, Acting AG Blanche, and DEA Administrator Terrance Cole. The government will have to defend both the substantive authority to issue the order and the procedural adequacy of how it was done. That's a two-front defense in a court that has a sophisticated administrative law docket.
The administrative hearing scheduled for next month on broader rescheduling - covering recreational products - adds another dimension. If the AG's order for medical products is struck down before that hearing concludes, the regulatory posture of the entire rescheduling process becomes genuinely uncertain. Licensed operators, compliance officers, and industry counsel need to hold that possibility close.
The cannabis industry has operated inside federal-state legal conflict for over a decade. This is not a new kind of risk - but it is a sharper one, arriving at a moment when many operators had reason to believe resolution was finally close.
